he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-04-25她自幼癫痫,34年来 “苦苦挣扎”,如今重拾生活想要
- 2022-04-21哪些是原发性癫痫病的一时期症状
- 2022-04-202013年国际抗癫痫联合会抗癫痫药物使用指南
- 2022-04-04病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 2022-03-2815为什么一岁的**患有睾丸癌值得警惕 ……
- 2021-11-04癫痫病饮食习惯治疗法包含哪些内容
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 诺华Cosentyx欧盟批准治疗中重度斑块状银屑病
- 绿激光 PVP 治疗顽固性尿潴留效果较好
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 首届辅助生殖-母婴健康高峰论坛在深圳罗湖区人民医院举行
- 病例学习:伴皮层下囊肿的巨脑性脑白质病
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- JAAD:紫外线光疗会增加湿疹患者皮肤癌的发病率吗?
- 预防银屑病复发的措施
- 箕星宣布aficamten在中国获得突破性治疗药物认定
- 15为什么一岁的**患有睾丸癌值得警惕 ……
- 白癜风的遗传是什么?
- 无精症的表现是什么,如何判断自己是否是无精症患者?
- 钙化怎么办
- 男性乳腺增生 为什么男性乳腺增生?
- 治疗白癜风的方法 牢记这些治疗白癜风更省钱
- 如何预防儿童白癜风?
- Clin Gastroenterology?H:?多潘立酮治疗对胃轻瘫症状的影响
- 与甘精胰岛素相比,礼来替西帕肽能显著降低糖化血红蛋白(A1c)水平
- 半年无业绩 国药控股先后出让投资公司75%股份
- 三庚酸酯可治疗1型转运体缺陷综合征
- 三种治疗花斑癣的偏方
- 诱发的原因是什么?
- 如何最有效地去除黑头?
- 晚餐吃什么减肥?这样吃饭很容易减肥
- 后天更早癫痫病症状能治疗吗
- 癫痫病的就有症状是什么样的
- 脑电图准不准?到底该认真哪种脑电图 ?
- 难治性癫痫病怎么顺利进行治疗
- 小儿良性癫痫病有什么病症
- 怎么化疗癫痫病
- 肖波教授接受丁香轩通讯员采访实录
- 成年癫痫的病征有哪些啊
- 引发癫痫的病因
- 太原癫痫病该医院:癫痫患者冬季易导致病情频繁发作
- 癫痫病发病究竟是没用
- 哮喘会遗传?不能同哮喘患者结婚?专家有话说
- 癫痫病的常见患者是什么样